英国研究证实，冠状动脉窦减速器(CSR)植入装置能够显著缓解难治性心绞痛患者的症状。一项包含491名患者的大型研究显示，75%的患者在植入后6个月内胸痛明显减少1。
该研究基于2014年至2024年间的数据，其中474名患者在英格兰和苏格兰的19家医院接受了植入手术1。患者反应积极，其中患者Cristian Jensen表示，手术后他的心绞痛发作频率从每周5次降低至每周1-2次，生活质量得到显著改善1。研究还显示，大多数患者在手术当天或次日即可出院，严重并发症罕见1。
尽管治疗效果显著，但在英国约300,000名难治性心绞痛患者中，目前仅有少数人接受了这种实验性治疗1。每个装置的成本为NHS 11,400英镑1。研究团队成员Dr Ranil de Silva表示，该装置"在这方面可能是一个改变者"1。
A British study demonstrates that a coronary sinus reducer (CSR) implant device significantly improves symptoms in patients with refractory angina, a severe heart condition resistant to conventional treatments. Research tracking 491 patients over a decade found that 75% experienced substantial chest pain reduction within six months of implantation.1
The large-scale observational study, conducted between 2014 and 2024, involved 474 patients who underwent implant surgery across 19 hospitals in England and Scotland.1 Most patients were discharged on the day of surgery or the following day, with serious complications remaining rare.1 At a cost of £11,400 per device to the National Health Service, the implant represents a potential breakthrough for the estimated 300,000 people in Britain who suffer from refractory angina, though only a limited number have received this experimental treatment to date.1
One patient, Cristian Jensen, saw his angina attacks decrease from five times weekly to one or two times weekly following the procedure, dramatically improving his quality of life.1 Dr. Ranil de Silva commented on the device's potential, stating: "It could be a game-changer in this area."1
评论
还没有评论，欢迎留下第一条。